A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma - Lindskog, Magnus; Laurell, Anna; Kjellman, Anders; Melichar, Bohuslav; Niezabitowski, Jacek; Maroto, Pablo; Zielinski, Henryk; Villacampa, Felipe; Bigot, Pierre; Bajory, Zoltan; Parikh, Omi; Alba, David Vazquez; et al. (Journal Of Clinical Oncology, 2020)